Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9.9Revenue (TTM) $M0.3Net Margin (%)-2,701.2Altman Z-Score-27.3
Enterprise Value $M7.2EPS (TTM) $-0.4Operating Margin %-3,964.8Piotroski F-Score2
P/E(ttm)--Beneish M-Score1.9Pre-tax Margin (%)-2,701.2Higher ROA y-yN
Price/Book1.010-y EBITDA Growth Rate %-16.9Quick Ratio1.7Cash flow > EarningsN
Price/Sales26.25-y EBITDA Growth Rate %-17.9Current Ratio1.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-47.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-62.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M29.2ROIC % (ttm)-144.2Gross Margin Increase y-yY

Gurus Latest Trades with HEB

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

HEB is held by these investors:



HEB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STRAYER DAVID RChief Science/Medical Officer 2017-05-02Buy7,937$0.63-46.03view
Pascale AdamCFO 2017-05-02Buy15,873$0.63-46.03view
Rodino Peter W. IIIExec Dir Govt Relations/Secrty 2017-05-02Buy15,873$0.63-46.03view
Springate Wayne S.Sr VP of Operations 2017-05-02Buy15,873$0.63-46.03view
Equels Thomas K.CEO, President 2017-04-27Buy72,464$0.69-50.72view
Equels Thomas K.CEO, President 2017-04-11Buy200,000$0.5-32view
Pascale AdamCFO 2017-02-16Buy6,981$0.46-26.09view
Springate Wayne S.Sr VP of Operations 2017-02-16Buy8,014$0.46-26.09view
STRAYER DAVID RChief Science/Medical Officer 2017-02-16Buy9,892$0.46-26.09view
Springate Wayne S.Sr VP of Operations 2017-02-16Buy8,014$0.46-26.09view

Press Releases about HEB :

Quarterly/Annual Reports about HEB:

News about HEB:

Articles On GuruFocus.com
Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended Jun Aug 15 2017 
Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was G Aug 14 2017 
Hemispherx Biopharma to Host Conference Call to Discuss Second Quarter Financial Results on Tuesday Aug 11 2017 
Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Can Aug 08 2017 
Hemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic Fat Aug 04 2017 
Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer Jul 10 2017 
Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities May 31 2017 
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017 May 15 2017 
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016 Mar 31 2017 
Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017 Mar 06 2017 

More From Other Websites
ETFs with exposure to Hemispherx Biopharma, Inc. : September 9, 2017 Sep 08 2017
ETFs with exposure to Hemispherx Biopharma, Inc. : August 25, 2017 Aug 25 2017
Edited Transcript of HEB earnings conference call or presentation 15-Aug-17 5:00pm GMT Aug 18 2017
Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Aug 16 2017
Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended... Aug 15 2017
Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was... Aug 14 2017
Hemispherx Biopharma to Host Conference Call to Discuss Second Quarter Financial Results on Tuesday,... Aug 11 2017
Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to... Aug 08 2017
Hemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic... Aug 04 2017
Today's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Hemispherx Biopharma Jul 11 2017
ETFs with exposure to Hemispherx Biopharma, Inc. : July 10, 2017 Jul 10 2017
Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer Jul 10 2017
ETFs with exposure to Hemispherx Biopharma, Inc. : June 28, 2017 Jun 28 2017
Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Jun 02 2017
ETFs with exposure to Hemispherx Biopharma, Inc. : May 8, 2017 May 08 2017
Edited Transcript of HEB earnings conference call or presentation 7-Apr-17 3:00pm GMT Apr 21 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}